Search | Clinical Trials Finder

Conditions: Ketorolac, Joint Fusion
Interventions: great toe (1st metatarsophalangeal joint) fusion, IV Ketorolac, Ketorolac Pill, 5/325mg Oxycodone-Acetaminophen, Aspirin 81Mg Ec Tab; Procedure · Drug
Lead sponsor: Rothman Institute Orthopaedics; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain
Interventions: Oxycodone HCl controlled-release tablets; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 6 Years to 16 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 35
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 31 more

Conditions: Readiness to Discharge
Interventions: Peri-Articular Injection, Epidural Pathway (PCEA+FNB); Procedure
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 85 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Nephrolithiasis
Interventions: Ketorolac Oral Tablet [Toradol], Acetaminophen, Oxycodone Acetaminophen; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: The Bronx, New York

Conditions: Pain
Interventions: Hydrocodone/acetaminophen, Placebo, Ibuprofen, Lorazepam, Lidocaine; Drug
Lead sponsor: Elizabeth Micks; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Abuse Potential
Interventions: Placebo, Oxycodone 20 mg, GE-IR 200 mg, GE-IR 450 mg; Drug
Lead sponsor: Arbor Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Human Abuse Potential
Interventions: Oxycodone 40 mg, Tramadol 600 mg, Placebo, Cebranopadol 600 µg, Cebranopadol 1000 µg; Drug
Lead sponsor: Tris Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Post Operative Pain
Interventions: Oxycodone oral capsule; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 19 Years to 40 Years · Female only
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Low Back Pain
Interventions: Oxycodone/Naloxone controlled-release, Oxycodone HCl controlled-release, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 149
States / cities: Alabaster, Alabama • Birmingham, Alabama • Foley, Alabama + 114 more

Conditions: Kidney Calculi, Ureteral Calculi
Interventions: Oxycodone, Ketorolac; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Osteoarthritis, Hip, Osteoarthritis, Knee, Lower Back Pain, Pain
Interventions: Oxycodone CR, Tapentadol (CG5503) ER; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 1,123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 40
States / cities: Mesa, Arizona • Tucson, Arizona • Anaheim, California + 37 more

Conditions: Abuse Potential
Interventions: gabapentin 600 mg, gabapentin 1200 mg, gabapentin 600 mg and oxycodone HCl 20 mg, gabapentin 1200 mg and oxycodone HCl 20 mg, oxycodone HCl 20 mg, placebo; Drug
Lead sponsor: Viatris Specialty LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Back Pain Lower Back Chronic
Interventions: Buprenorphine, Oxycodone Immediate-Release; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 660 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 85
States / cities: Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 72 more

Conditions: Shoulder Pain, Hiatal Hernia
Interventions: Resteck Shiatsu Neck and Back Massager, Marcaine; Device · Drug
Lead sponsor: Norton Thoracic Institute; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Low Back Pain, Pain, Pain, Intractable
Interventions: Cognitive behavioral therapy, Pain self-management program, Co-Analgesic Therapy, Opioid Analgesics; Behavioral · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Low Back Pain
Interventions: Oxycodone/Naloxone Controlled-release, Placebo; Drug
Lead sponsor: Purdue Pharma LP; Industry
Eligibility: 18 Years and older
Enrollment: 1,095 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 151
States / cities: Birmingham, Alabama • Haleyville, Alabama • Huntsville, Alabama + 123 more

Conditions: Osteoarthritis
Interventions: celecoxib, Oxycodone, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Healthy
Interventions: Test formulation administered with water, Test formulation administered with 20% ethanol, Test formulation administered with 40% ethanol; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Noncancer Pain
Interventions: oxycodone HCl and naltrexone HCl extended-release capsules; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 32
States / cities: DeLand, Florida • Jacksonville, Florida • Jupiter, Florida + 27 more

Conditions: Healthy
Interventions: Oxycodone controlled-release test formulation, Immediate-release reference drug; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: PF614, Oxycodone extended-release, Naltrexone Hydrochloride; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Postoperative Pain, Inflammation, Osteoarthritis
Interventions: Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo; Drug
Lead sponsor: Thomas L Bradbury; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Pain
Interventions: Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule; Drug
Lead sponsor: BioDelivery Sciences International; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 3
States / cities: Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah

Conditions: Chronic Low Back Pain, Degenerative Disc Disease, Depression, Anxiety
Interventions: Oxycodone, Morphine, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 75 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Chestnut Hill, Massachusetts

Search by objective public record fields.

Effect of Postoperative Ketorolac on Bone Healing After Joint Fusion

Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Children With Moderate to Severe Malignant and/ or Nonmalignant Pain Requiring Opioids

Analgesia After Total Knee Arthroplasty: Peri-Articular Injection Versus Epidural + Femoral Nerve Blockade

Pain Outcomes of Non-opioid vs. Opioid Analgesia for Kidney Stone Surgery.

Hydrocodone For Pain Control in First Trimester Surgical Abortion

Abuse Potential of HORIZANT With and Without Oxycodone in Healthy, Nondependent Recreational Opioid Users

Assessment of Abuse Potential of Cebranopadol in Humans

Too Much of a Good Thing? Impact of Initial Prescription Size in Post-cesarean Section Pain Management

A Study of Oxycodone/Naloxone Controlled-release Tablets (OXN) to Assess Analgesic Efficacy and Management of Opioid-induced Constipation (OIC) in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Study of Ketorolac Versus Opioid for Pain After Endoscopy

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Study Evaluating the Abuse Potential of NEURONTIN® in Healthy Non-drug Dependent, Recreational Opioid Users

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

Pain Relief After Hiatal Hernia Repair Surgery

Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)

Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Back Pain

Measuring Gait And Self-Reported Pain In Patients With Osteoarthritis Of The Knee Using Placebo/Oxycodone/Celecoxib.

Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

Study of PF614 Compared to OxyContin® in Healthy Volunteers (PF614-101)

Steroids in Total Knee Arthroplasty

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

Opioid Treatment for Chronic Low Back Pain and the Impact of Mood Symptoms